An Overview of Pulmonary Arterial Hypertension (PAH): Update on Clinical Considerations & Diagnosis

MODULE PAH-101

Supported by an educational grant from Actelion

TITLE - An Overview of Pulmonary Arterial Hypertension (PAH): Update on Clinical Considerations & Diagnosis

TARGET AUDIENCE - Target audiences for this program are Specialty Pharmacists, Pharmacists, Clinical Pharmacists, Specialty Pharmacy executives, Pharmacy Directors, Chief Pharmacy Officers, Pulmonary Pharmacists, Pulmonary Nurses and Nurses

LEARNING OBJECTIVES - After completing the program, Specialty Pharmacists, Pharmacists, Clinical Pharmacists, Specialty Pharmacy executives, Pharmacy Directors, Chief Pharmacy Officers, Pulmonary Pharmacists, Pulmonary Nurses and Nurses, along with other healthcare practitioner participants will be able to:

  1. Describe the etiology, pathophysiology and risk factors of pulmonary arterial hypertension (PAH)
  2. List signs and symptoms of PAH
  3. Define diagnostic criteria for the WHO Group 1 PAH
  4. Differentiate WHO Group 1 with other WHO groups of pulmonary hypertension
  5. Identify the functional class of PAH based on a symptomatic profile

Faculty Disclosures:

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/ services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by the Specialty Pharma Education Center for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Pharmacist continuing education credit

Specialty Pharma Education Center (SPEC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.5 hours (0.15CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
ACPE #0535-0000-17-005-H01-P

Knowledge Based Activity

Course release date 2/14/2017

Course expires 2/14/2020

Nursing continuing education credit

Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.  Provider # 5-115.  This program is approved for 1.5 hours of continuing nursing education.

Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.

Program launch 4/13/2017

Program expires 4/13/2019

Credit Information

Activity Number Credit Amount Accreditation Period
0535-0000-17-005-H01-P 0.15 CEUs February 14, 2017 - February 14, 2020
0535-0000-17-005-H01-N 1.5 hours of CNE April 13, 2017 - April 13, 2019